What is the recommended dosing and administration of macrogol (polyethylene glycol) for treating constipation in children, including infants under 2 years?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Macrogol (Polyethylene Glycol) for Constipation in Children

Polyethylene glycol (PEG/macrogol) is safe and effective for treating constipation in children of all ages, including infants under 2 years, with a recommended maintenance dose of approximately 0.7-0.8 g/kg/day.

Dosing by Age Group

Infants Under 18 Months

For infants younger than 18 months, the recommended maintenance dose is 0.78 g/kg/day (range 0.26-1.26 g/kg/day) 1. This dose has been shown to relieve constipation in 97.6% of patients with minimal side effects 1. The evidence demonstrates similar safety and efficacy profiles to older children, though systematic reviews note that optimal dosing regimens for infants under 24 months remain variable across studies, ranging from 0.45-1.1 g/kg/day for PEG 3350 2.

Children Over 18 Months

For older children, maintenance dosing of 0.7 g/kg/day is effective 3. While lower doses (0.3 g/kg/day) can achieve treatment success, they require more frequent dose adjustments and result in lower parental satisfaction 3.

Adolescents and Adults (17+ years)

The standard adult dose is 17 g once daily mixed in 4-8 ounces of beverage 4. This dose should not be used for more than 7 days without physician guidance for over-the-counter use 4.

Treatment Approach

Initial Management

  • Start with 0.7-0.8 g/kg/day for maintenance therapy in children
  • Ensure powder is fully dissolved before drinking 4
  • Can be mixed in cold, hot, or room temperature beverages 4
  • Do not combine with starch-based thickeners 4

Disimpaction (Fecal Impaction)

When fecal impaction is present, higher doses of 1.0-1.5 g/kg/day for 3 days are effective, achieving disimpaction in 95% of children 5. These higher doses are significantly more effective than lower doses (0.25-0.5 g/kg/day) for clearing impaction 5.

Duration of Therapy

  • PEG can be used safely for extended periods (≥6 months to 18+ months) 6
  • Mean duration in clinical practice is approximately 18.6 months without need for dose adjustment due to weight gain 6
  • Long-term use normalizes bowel movements and improves clinical symptoms without serious adverse events 6

Safety Profile

PEG is remarkably safe across all pediatric age groups, including infants 1. Common adverse effects are:

  • Transient diarrhea (13%) - resolves with dose adjustment 1, 5
  • Bloating (18%) - more common with higher doses 5
  • Abdominal cramping (5%) 5
  • Increased gas 1

Critical safety point: No clinically significant electrolyte changes occur with PEG use 5. Gastrointestinal adverse events decrease markedly after the first week of treatment 7.

Alternative for Infants

For infants with constipation, fruit juices containing sorbitol (prune, pear, apple) can increase stool frequency and water content as an alternative or adjunct approach 8. However, PEG remains the primary evidence-based osmotic laxative.

Pregnancy Considerations

PEG is safe during pregnancy 9. Osmotic laxatives like PEG and lactulose can be administered safely, though excessive fiber and lactulose may cause maternal bloating 9.

Key Clinical Pearls

  • Dose titration is essential: Adjust based on response (target ≥3 bowel movements/week with no soiling) 3
  • Higher initial doses work better for impaction: Don't underdose when clearing fecal impaction 5
  • Long-term use is appropriate: Unlike the FDA label suggesting 7-day limits for OTC use, clinical evidence supports months-long therapy 6
  • No need for dose escalation with growth: Children maintain effective symptom control on stable doses despite weight gain 6
  • Treatment success definition: ≥3 complete spontaneous bowel movements per week with an increase of ≥1 from baseline 7

Avoid stimulant laxatives in children, as safety data are conflicting 9. PEG should be the first-line osmotic laxative choice over alternatives like lactulose, which may cause more bloating 9, 10.

Related Questions

What is the appropriate dose of MiraLAX (polyethylene glycol 3350) for a 2‑year‑old child weighing approximately 12–14 kg?
What is the appropriate dose of polyethylene glycol 3350 (MiraLAX) for a 21‑month‑old child?
Is giving a pediatric patient a Restorafibre gummy (fiber supplement) in addition to Restoralax (polyethylene glycol 3350) 7 g daily an appropriate bowel regimen for constipation with excessive gastrointestinal gas, bloating, and discomfort while fecal occult blood testing and fecal calprotectin are being performed?
What is the appropriate dose of MiraLAX (polyethylene glycol 3350) for a 19‑month‑old child weighing approximately 24 lb (≈11 kg) with constipation, and how should it be administered?
What is the appropriate dose of polyethylene glycol 3350 (Miralax) for a 3‑year‑old child weighing 32 lb (≈14.5 kg) with constipation?
What is the recommended dosing regimen of apixaban for treatment and prophylaxis of venous thromboembolism in adults, including adjustments for age, weight, and renal function?
In a patient receiving Advate (recombinant factor VIII) prophylaxis with emicizumab (Hemlibra) every 4 weeks who develops a hematoma, what laboratory tests and assessment/management plan should be performed?
In a patient on carbamazepine with a progressive decrease in neutrophils resulting in an absolute neutrophil count of 1.75 × 10⁹/L, should the drug be continued with monitoring or discontinued?
Is cefepime safe for use during pregnancy, and what dosing adjustments are recommended for a pregnant adult with normal renal function?
Which monitoring tests should be performed for a 35‑year‑old male five years after renal transplantation who is taking mycophenolate mofetil (Renodapt S) 720 mg in the morning and 360 mg in the evening, prednisone (Wysolone) 5 mg each morning, tacrolimus 1 mg in the morning and 0.75 mg in the evening, amlodipine 5 mg daily, telmisartan 20 mg daily, and metoprolol extended‑release 25 mg daily?
What is the recommended dosage and administration of macrogol (polyethylene glycol) for treating functional constipation in children?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.